4/18
04:09 pm
vstm
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer [Yahoo! Finance]
Medium
Report
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer [Yahoo! Finance]
4/18
04:05 pm
vstm
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
Medium
Report
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
4/11
08:14 am
vstm
Orna Therapeutics Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer [Yahoo! Finance]
Low
Report
Orna Therapeutics Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer [Yahoo! Finance]
4/11
08:14 am
vstm
MPM BioImpact Appoints Frank Neumann, M.D., Ph.D., Distinguished Expert in Clinical Development, as Entrepreneur Partner [Yahoo! Finance]
Low
Report
MPM BioImpact Appoints Frank Neumann, M.D., Ph.D., Distinguished Expert in Clinical Development, as Entrepreneur Partner [Yahoo! Finance]
4/9
07:00 am
vstm
GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting
Low
Report
GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting
4/4
07:30 am
vstm
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/19
08:09 am
vstm
Verastem, Inc. (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.50 price target on the stock.
Low
Report
Verastem, Inc. (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.50 price target on the stock.
3/18
02:56 pm
vstm
Verastem, Inc. (NASDAQ: VSTM) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $32.00 price target on the stock.
Low
Report
Verastem, Inc. (NASDAQ: VSTM) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $32.00 price target on the stock.
3/18
07:00 am
vstm
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
Low
Report
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
3/14
04:21 pm
vstm
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates [Yahoo! Finance]
Medium
Report
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates [Yahoo! Finance]
3/14
04:05 pm
vstm
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
Medium
Report
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
3/12
11:02 pm
vstm
Verastem, Inc. (NASDAQ: VSTM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Verastem, Inc. (NASDAQ: VSTM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/11
07:30 am
vstm
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
Low
Report
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
3/6
05:56 am
vstm
Verastem gets FDA orphan drug status for low-grade ovarian cancer therapy [Seeking Alpha]
Low
Report
Verastem gets FDA orphan drug status for low-grade ovarian cancer therapy [Seeking Alpha]
3/5
05:27 pm
vstm
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
Low
Report
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
3/5
04:43 pm
vstm
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024 [Yahoo! Finance]
Low
Report
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024 [Yahoo! Finance]
3/5
04:30 pm
vstm
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
Low
Report
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
2/15
03:21 am
vstm
Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc [Yahoo! Finance]
Low
Report
Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc [Yahoo! Finance]
2/15
01:15 am
vstm
Verastem, Inc. (NASDAQ: VSTM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Verastem, Inc. (NASDAQ: VSTM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
2/7
05:10 pm
vstm
Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM) [Yahoo! Finance]
Neutral
Report
Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM) [Yahoo! Finance]
2/7
01:23 am
vstm
Verastem: Other Catalysts In 2024 Beyond NDA Rolling Submission Of Defactinib [Seeking Alpha]
Medium
Report
Verastem: Other Catalysts In 2024 Beyond NDA Rolling Submission Of Defactinib [Seeking Alpha]
2/6
10:02 pm
vstm
Verastem, Inc. (NASDAQ: VSTM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Verastem, Inc. (NASDAQ: VSTM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
1/29
07:00 am
vstm
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
Medium
Report
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers